Xcellogen Biotech India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2019
About Xcellogen Biotech India
Xcellogen Biotech India Private Limited (XBIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 05 September 2018 (Six years and four months 29 days old ). Its registered office is in Kanyakumari, Tamil Nadu, India.
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sheelakumari Anooj, Thanappan Kumar, and Amrutha Makool serve as directors at the Company.
Company Details
-
Location
Kanyakumari, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U73100TN2018PTC124405
-
Company No.
124405
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Sep 2018
-
Date of AGM
31 Dec 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Xcellogen Biotech India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thanappan Kumar
|
Director | 05-Sep-2018 | Current |
|
Sheelakumari Anooj
|
Director | 05-Sep-2018 | Current |
|
Amrutha Makool
|
Director | 08-Dec-2018 | Current |
Financial Performance of Xcellogen Biotech India.
Xcellogen Biotech India Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xcellogen Biotech India?
Unlock access to Xcellogen Biotech India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xcellogen Biotech India?
Unlock and access historical data on people associated with Xcellogen Biotech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xcellogen Biotech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xcellogen Biotech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.